Journal
CELL CYCLE
Volume 8, Issue 11, Pages 1654-1658Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.8.11.8544
Keywords
caveolin-1; stroma; cancer-associated fibroblasts; prognosis; treatment stratification; biomarkers; breast cancer
Categories
Funding
- NIH/NCI [R01-CA-80250, R01-CA098779, R01-CA-120876, R01-CA-090876, R01-CA-107469, R01-CA-70896, R01-CA-75503, R01-CA-86072, R01-CA-107382, P30-CA-56036]
- American Association for Cancer Research (AACR)
- Susan G. Komen Breast Cancer Foundation
- Department of Defense-Breast Cancer Research Program (Synergistic Idea Award)
- Breast Cancer Alliance, Inc.
- Susan G. Komen Career Catalyst Grant
- Elsa U. Pardee Foundation
- W. W. Smith Charitable Trust
- Breast Cancer Alliance
- American Cancer Society (ACS)
- Avon Foundation
- Dr. Ralph and Marian C. Falk Medical Research Trust
- Pennsylvania Department of Health
- NATIONAL CANCER INSTITUTE [K08CA090876, R01CA070896, P30CA056036, R01CA107382, R01CA107469, R01CA080250, R01CA075503, R01CA120876, R01CA086072, R01CA098779] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Here, we discuss recent evidence that an absence of stromal Cav-1 expression in human breast cancers is a powerful single independent predictor of early disease recurrence, metastasis and poor clinical outcome. These findings have now been validated in two independent patient populations. Importantly, the predictive value of stromal Cav-1 is independent of epithelial marker status, making stromal Cav-1 a new universal or widely-applicable breast cancer prognostic marker. We propose based on the expression of stromal Cav-1, that breast cancer patients could be stratified into high-risk and low-risk groups. High-risk patients showing an absence of stromal Cav-1 should be offered more aggressive therapies, such as anti-angiogenic approaches, in addition to the standard therapy regimens. Mechanistically, loss of stromal Cav-1 is a surrogate biomarker for increased cell cycle progression, growth factor secretion, stemness, and angiogenic potential in the tumor microenvironment. Since almost all cancers develop within the context of a stromal microenvironment, this new stromal classification system may be broadly applicable to other epithelial and non-epithelial cancer subtypes, as well as pre-malignant lesions (carcinoma in situ).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available